David Cavalla
Oprichter bij Exvastat Ltd.
Profiel
David Cavalla is the founder of Exvastat Ltd.
which was founded in 2016, where he holds the title of Chief Executive Officer & Director.
He is currently a Director at Numedicus Ltd.
since 2008.
Dr. Cavalla's former positions include being a Principal at GSK Products, Inc. and National Institute of Mental Health.
Dr. Cavalla received a doctorate degree from the University of Cambridge.
Actieve functies van David Cavalla
| Bedrijven | Functie | Begin |
|---|---|---|
Exvastat Ltd.
 Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom. | Oprichter | 01-01-2016 |
Numedicus Ltd.
 Numedicus Ltd. BiotechnologyHealth Technology Numedicus Ltd. is a world-class drug repurposing British company founded in 2008. The private company is based in Cambridge, UK. Numedicus has identified several clinical-stage drug repurposing projects supported by method-of-use patents. The company uses therapeutic switching to identify secondary uses for existing drugs in practically all areas. David Cavalla, the founder, has 35 years of experience in various senior scientific and commercial roles within the pharmaceutical industry. He is one of the first advocates of drug repurposing and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. The company's latest news includes the start of a phase II trial in severe COVID-19 patients. | Directeur/Bestuurslid | 08-12-2008 |
Eerdere bekende functies van David Cavalla
| Bedrijven | Functie | Einde |
|---|---|---|
| National Institute of Mental Health | Corporate Officer/Principal | - |
GSK Products, Inc.
 GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Corporate Officer/Principal | - |
Opleiding van David Cavalla
| University of Cambridge | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
GSK Products, Inc.
GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Distribution Services |
| National Institute of Mental Health | Government |
Exvastat Ltd.
Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Numedicus Ltd.
Numedicus Ltd. BiotechnologyHealth Technology Numedicus Ltd. is a world-class drug repurposing British company founded in 2008. The private company is based in Cambridge, UK. Numedicus has identified several clinical-stage drug repurposing projects supported by method-of-use patents. The company uses therapeutic switching to identify secondary uses for existing drugs in practically all areas. David Cavalla, the founder, has 35 years of experience in various senior scientific and commercial roles within the pharmaceutical industry. He is one of the first advocates of drug repurposing and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. The company's latest news includes the start of a phase II trial in severe COVID-19 patients. | Health Technology |